BioSpace News Archive

Site contains links to information about post-COVID-19 long-hauler syndrome An article published yesterday in the San Francisco Chronicle references diarrhea as long-hauler symptom and the theory that the type of inflammation associated with HIV may also be present in long-hauler patients Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in long-hauler COVID-19 recovery patients in Europe SAN F

Propella Therapeutics Inc. (Propella), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), part of the National Institutes of Health, have entered into a Cooperative Research and Development Agreement (CRADA).

BioPhotas, Inc., the global market leader in therapeutic LED Light Therapy devices announced four new aesthetic industry awards for its continued focus on product innovation.

SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the fourth quarter and full year 2020 after the market closes on Thursday, February 25, 2021.

TerSera Therapeutics LLC announced today that cetirizine has been added by the Centers for Disease Control and Prevention (CDC) as an adjunctive therapy to its guidelines titled, “Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination.”

Glatt Pharmaceutical Services and Aprecia announce their joint effort to accelerate and expand the use of Glatt’s multiparticulate technologies through Aprecia’s 3DP manufacturing

David Hunter, MBBS, PhD, a renowned clinical researcher and rheumatology expert based in Australia, has joined the scientific leadership of George Clinical, a global scientifically-backed clinical research organization.

JDRF, the leading global organization funding type 1 diabetes research, announces, in collaboration with the Harvard Stem Cell Institute, the launch of the JDRF Center of Excellence in New England.

Satisfi Labs, the conversational AI platform for destinations and experiences, today announced the launch of its Vaccine Site Assistant to help venues leveraging their sites as vaccine centers, for free to anyone in need.